Shots:

• Clover plans to initiate a global P-II/III efficacy trial with the S-Trimer COVID-19 vaccine candidate adjuvanted with CpG 1018 plus alum in the H1’2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021
• Additionally- Clover discontinued their partnership with GSK to evaluate the S-Trimer vaccine candidate with GSK's pandemic adjuvant system
• The CEPI will continues to support Clover's COVID-19 vaccine candidate and will fund its development through licensure

 ­ Ref: PRNewswire | Image: Siakap Keli